Investor Presentation January 2026 Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek's market position and long-term market expansion opportunities; Cytek's business, product and operational goals and strategies; and Cytek's opp ...

Core Insights - BD (Becton, Dickinson and Company) has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to enhance research in deep human immune profiling and support the development of immune-mediated therapies [1][2] Group 1: Collaboration Details - The collaboration aims to develop and validate a high-parameter flow cytometry panel that captures key functional pathways in whole blood, including phosphorylation markers, to provide insights into single-cell responses to drugs or disease states [2] - A planned 1,000-patient immune profiling study will be conducted in partnership with the Penn Colton Center for Autoimmunity, expected to commence in the summer [2] - The project will utilize the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, and BD reagents, with BD teams managing reagents, instrumentation, and spectral data algorithms, while I3H teams will serve as scientific and clinical leads [2] Group 2: Technological Advancements - The BD FACSDiscover™ A8 Cell Analyzer is highlighted as the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, which will facilitate deeper insights into the human immune system [3] - The collaboration reflects a commitment to advancing science and health through the unlocking of the human immune system's potential [3] Group 3: Industry Impact - High-parameter single-cell studies are becoming increasingly central to understanding the human immune system, with BD's ecosystem of flow cytometers, single-cell systems, reagents, software, and informatics providing essential support for organizations like I3H [4] - The collaboration aims to translate immunological insights into quantitative, actionable information for discovery and clinical care teams globally [4]

Core Insights - Cytek Biosciences, Inc. has been awarded the title of Drug Discovery Solution of the Year for its Cytek Muse Micro cell analyzer at the 2025 BioTech Breakthrough Awards, recognizing its innovative contributions to the life sciences and biotechnology sectors [1][3][10] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Product Highlights - The Cytek Muse Micro cell analyzer enhances the original Guava Muse system, offering a compact, cost-effective, and multifunctional platform that simplifies flow cytometry while maintaining accuracy and versatility [2][4] - Applications of the Muse Micro system include cell counting, cell health and viability assessment, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis [2] Market Impact - The Muse Micro system aims to democratize access to sophisticated cell analysis, making it more accessible for smaller labs and resource-limited facilities, which traditionally faced barriers due to the complexity and cost of traditional flow cytometry systems [3][4]

Disease Diagnosis and Treatment - Hematopathology specializes in diagnosing diseases associated with blood, bone marrow, lymph nodes, and clotting mechanisms, utilizing advanced techniques like flow cytometry and molecular diagnostics [1] - Flow cytometry is used to convert cells into dots on a plot, aiding in the diagnosis and monitoring of blood cancers [3] - Measurable Residual Disease (MRD) detection via flow cytometry helps assess therapy effectiveness [4] - CAR T-cell therapy, where a patient's own immune cells are trained to fight cancer cells, shows promise in treating relapsed blood cancers [4] Technological Advancements - Flow cytometers use optics, fluidics, and electronics to analyze cells, detecting fluorescently labeled antibodies bound to antigens [3] - The integration of clinical knowledge, immunology, flow cytometry, and molecular biology is crucial for modern hematology [4] Impact and Training - Tata Memorial Center sees approximately 4,000 new blood cancer patients annually [4] - The center provides training to dozens of trainees, technicians, and pathologists from across the country and neighboring countries, focusing on understanding the science behind the data [4] - The ultimate goal is to provide patients with second chances, hope, and the opportunity to live out their dreams [4][5]